In October 2026, Nuance Pharma announces the first patient dosed in the REACH Phase III trial, a randomized, double-blind, ...
Over 70% of patients achieved PASI 90 and more than 80% reached PGA 0/1 at Week 16, demonstrating significant efficacy over placebo with no new safety signals.
Expanded agreement grants Simcere exclusive commercialisation rights across mainland China, Hong Kong, Macau and Taiwan, building on the drug’s completed Phase III trial and NDA acceptance in April ...
CB03-154, a next-generation potassium-channel opener, targets neuronal excitability, with topline results expected in Q3 2027 and a potential conditional approval application to follow. Shanghai ...
Backed by GSK, Pfizer and Sanofi, the Cascade initiative will integrate single-cell sequencing and protein data to strengthen predictive models of human immune responses.
Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive ...
Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide ...
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
Accord now holds two pegfilgrastim biosimilars in one market, its in-house Ennumo and the acquired Udenyca. Owning both the ...
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...
Despite missing primary endpoints, the endocannabinoid modulator demonstrated encouraging pain score improvements in subgroup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results